J CRAIG VENTER INSTITUTE INC: Form 990, tax year 2020
View the entire original 990 at ProPublica ↗
- Organization
- J CRAIG VENTER INSTITUTE INC (EIN 52-1842938)
- Tax period
- 2020-01-01 to 2020-12-31
- Filed
- 2021-11-12
- IRS object ID
- 202143169349306499
- Schema version
- 2020v4.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2021-11-12T12:28:57-06:00 | ReturnTs |
| Tax Period End | 2020-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 910189318 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MOSS ADAMS LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4747 EXECUTIVE DR SUITE 1300 | AddressLine1Txt |
| City | SAN DIEGO | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 92121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2020-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 521842938 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | J CRAIG VENTER INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | JCRA | BusinessNameControlTxt |
| Phone | 8582001800 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4120 CAPRICORN LANE | AddressLine1Txt |
| City | LA JOLLA | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 92037 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | JOHN CRAIG VENTER | PersonNm |
| Person Title | CHAIRMAN AND CEO | PersonTitleTxt |
| Phone | 8582001800 | PhoneNum |
| Signature | 2021-11-11 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | JOHN | PersonFirstNm |
| Person Last | CRAIG VENTER | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | PATRICIA J MAYER | PreparerPersonNm |
| PTIN | P00188643 | PTIN |
| Phone | 8586271400 | PhoneNum |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 2 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2020 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | JOHN CRAIG VENTER | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4120 CAPRICORN LANE | AddressLine1Txt |
| City | LA JOLLA | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 92037 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $28,482,912 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.JCVI.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1993 | FormationYr |
| Legal Domicile State | MD | LegalDomicileStateCd |
| Activity Or Mission | JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MOREABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERSABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL. | ActivityOrMissionDesc |
| Voting Members Governing Body | 8 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 5 | VotingMembersIndependentCnt |
| Total Employee | 180 | TotalEmployeeCnt |
| Total Volunteers | 7 | TotalVolunteersCnt |
| Total Gross UBI | $15,294 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $21,442,951 | PYContributionsGrantsAmt |
| CY Contributions Grants | $18,613,419 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $420,120 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $123,655 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,920,374 | PYInvestmentIncomeAmt |
| CY Investment Income | -$823,759 | CYInvestmentIncomeAmt |
| PY Other Revenue | $6,009 | PYOtherRevenueAmt |
| CY Other Revenue | $15,294 | CYOtherRevenueAmt |
| PY Total Revenue | $23,789,454 | PYTotalRevenueAmt |
| CY Total Revenue | $17,928,609 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $2,586,471 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,842,807 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $21,730,028 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $19,124,778 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $686,812 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $13,109,263 | PYOtherExpensesAmt |
| CY Other Expenses | $8,407,194 | CYOtherExpensesAmt |
| PY Total Expenses | $37,425,762 | PYTotalExpensesAmt |
| CY Total Expenses | $30,374,779 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$13,636,308 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$12,446,170 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $108,987,608 | TotalAssetsBOYAmt |
| Total Assets EOY | $100,269,815 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $35,167,258 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $36,854,821 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $73,820,350 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $63,414,994 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MORE ABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERS ABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $7,864,788 | ExpenseAmt |
| Grant | $2,782,839 | GrantAmt |
| Revenue | $123,655 | RevenueAmt |
| Desc | THROUGHOUT THE FISCAL YEAR 2020, THE JCVI RECEIVED FUNDING FROM VARIOUS FEDERAL AND NON-FEDERAL SPONSORING AGENCIES AND FOUNDATIONS SUPPORTING IN EXCESS OF 85 ACTIVE RESEARCH PROJECTS COVERING A RANGE OF RESEARCH AREAS INCLUDING HUMAN HEALTH, ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, TECHNOLOGY AND TOOLS, EDUCATION AND POLICY. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS) -FUNDED BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID/NIH) AND IN COLLABORATION WITH THE UNIVERSITY OF CHICAGO, THE JCVI SERVES AS THE MAIN DEVELOPER OF THE VIRAL PATHOGEN RESOURCE (WWW.VIPRBRC.ORG) AND THE INFLUENZA RESEARCH DATABASE (WWW.FLUDB.ORG). THESE RESOURCES SERVE AS FREE PUBLIC PORTALS TO A WIDE RANGE OF INFORMATION, DATA, AND ANALYTICAL TOOLS FOR INTERPRETING VIRAL GENOMES IN THE CONTEXT OF DISEASE. OVER 3000 RESEARCHERS THROUGHOUT THE WORLD USE THESE RESOURCES EVERY WEEK. JCVI CONTINUED TO LEAD A 5-YEAR COLLABORATIVE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS/NIH) GRANT WITH THE GOAL TO DEVELOP, VALIDATE AND DISSEMINATE A COMPUTATIONAL INFRASTRUCTURE FOR UNBIASED ANALYSIS OF CYTOMETRY DATA FOR BOTH DIAGNOSTIC AND DISCOVERY APPLICATIONS THAT COULD HELP OVERCOME THE CURRENT LIMITATIONS OF MANUAL ANALYSIS AND PROVIDE FOR MORE EFFICIENT, OBJECTIVE, ACCURATE, AND REPRODUCIBLE ANALYSIS OF CYTOMETRY DATA. FLOW CYTOMETRY ANALYSIS IS WIDELY USED IN TRANSLATIONAL RESEARCH LAB TO EXPLORE THE MECHANISMS OF NORMAL AND ABNORMAL BIOLOGICAL PROCESSES AND IN THE CLINICAL DIAGNOSTIC LAB FOR THE IDENTIFICATION AND CLASSIFICATION OF BLOOD-BORNE MALIGNANCIES. HOWEVER, THE CURRENT PRACTICE FOR CYTOMETRY DATA ANALYSIS RELIES ON SUBJECTIVE AND AD HOC "MANUAL GATING". THE PROJECT TEAM OF JCVI, THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (UCSD), THE UNIVERSITY OF CALIFORNIA, IRVINE (UCI), AND STANFORD UNIVERSITY COLLABORATED TO CONTINUE IMPROVING THE ACCESSIBILITY, FUNCTIONALITY, AND USABILITY OF THE PROPOSED INFRASTRUCTURE. THE PROJECT TEAMS ASSEMBLED MULTIPLE FLOW CYTOMETRY DATASETS FROM IMPORTANT BIOMEDICAL PROJECTS CONDUCTED BY TRANSLATIONAL RESEARCHERS AT UC IRVINE AND FROM THE CLINICAL DIAGNOSTICS LAB AT UCSD. THE JCVI TEAM PROCESSED AND ANALYZED THE DATASETS USING THE COMPUTATIONAL INFRASTRUCTURE AND VALIDATED THE ANALYSIS RESULTS USING FOLLOW-UP STUDIES. THE COMPUTATIONAL ANALYSES OF THESE DATASETS HAVE IDENTIFIED NOVEL CELL SUBSETS FROM HUMAN LEUKOCYTES FOR INDEPENDENT ASTHMA RESEARCH PROJECTS BEING CONDUCTED AT PEDIATRICS OF UC IRVINE. THE ANALYSES HAVE ALSO IDENTIFIED A NOVEL COMBINATION OF CELL SURFACE MARKERS FOR PRECISION DIAGNOSIS OF THE CHRONIC LYMPHOCYTIC LEUKEMIA BASED ON THE CLINICAL FLOW CYTOMETRY DATA PROVIDED BY UCSD. THE RESULTS AND FINDINGS HAVE BEEN PUBLISHED ON PEER-REVIEWED JOURNALS OR REPORTED AT SCIENTIFIC CONFERENCES. THE PROJECT TEAM HAVE ALSO BEEN TRAINING THE TRANSLATIONAL RESEARCHERS OF UCI PEDIATRICS AND HEMATOPATHOLOGISTS OF UCSD PATHOLOGY FOR USING THE ADVANCED DATA ANALYTICS TOOLS ON THE COMPUTATIONAL INFRASTRUCTURE THROUGH IN-PERSON SITE VISITS AND WEBEX MEETINGS. FUNDED THROUGH THE NATIONAL INSTITUTE OF ALLERGY AND IMMUNOLOGY (NIAID/NIH) AND IN COLLABORATION WITH NORTHEASTERN UNIVERSITY. ANTIBIOTIC RESISTANCE CONTINUES TO BE ONE OF THE BIGGEST PUBLIC HEALTH PROBLEMS OF OUR TIME. JCVI IN COLLABORATION WITH NORTHEASTERN UNIVERSITY HAVE DEVELOPED NEW METHODS TO GROW AND EXPLOIT PREVIOUSLY UNCHARACTERIZED MICROBES. JCVI DEVELOPED A TRANSCRIPTION-BASED PLATFORM THAT BIOINFORMATICALLY PREDICTS WHETHER NEW POTENTIAL COMPOUNDS ARE EXPRESSING ANTIBIOTIC PROPERTIES WITH NOVEL MECHANISMS OF ACTION. PROMISING COMPOUNDS ARE VALIDATED AND BECOME LEAD ANTIMICROBIAL COMPOUNDS FOR FURTHER STUDY. AS PART OF AN NIH GRANT IN COLLABORATION WITH COLLEAGUES AT UC IRVINE, THE RESEARCH TEAM HAVE BEEN APPLYING ADVANCE LABORATORY, COMPUTATIONAL, AND ARTIFICIAL INTELLIGENCE METHODS TO EXPLORE WHY SOME PEOPLE INFECTED WITH SARS-COV-2 DEVELOP SEVERE DISEASE WHILE OTHERS ARE ASYMPTOMATIC OR ONLY DEVELOP MILD SYMPTOMS. WE HAVE ALSO EXPLORED THE IMPACT THAT CORTICOSTEROID TREATMENT HAS ON COVID PATIENTS. WE FOUND THAT WHILE SEVERE COVID PATIENTS MOUNT AN EFFECTIVE ANTIBODY RESPONSE, THEY ALSO DEVELOP A MORE SEVERE GENERAL INFLAMMATORY REACTION, AND THAT THIS INFLAMMATORY RESPONSE WAS DAMPENED WITH STEROID TREATMENT. THESE FINDINGS SUGGEST THAT STEROID-BASED INTERVENTIONS COULD POTENTIAL LIMIT SEVERE COVID DISEASE AND WERE REPORTED IN A RECENT PUBLICATION IN THE JOURNAL OF LEUKOCYTE BIOLOGY (HTTPS://JLB.ONLINELIBRARY.WILEY.COM/DOI/EPDF/10.1002/JLB.4COVA0121-084RR). FUNDED BY NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS/NIH) MICROBIOME IN ASTHMA INDUCED BY ENVIRONMENTAL PARTICLE EXPOSURE. IN COLLABORATION WITH BROWN UNIVERSITY. MICROBIAL DYSBIOSIS IN THE GUT AND THE LUNG IS INCREASINGLY BEING ASSOCIATED WITH THE INCIDENCE AND SEVERITY OF ASTHMA, HOWEVER CAUSALITY STUDIES ARE LACKING. JCVI AND ITS COLLABORATOR, BROWN UNIVERSITY HAVE ADAPTED A MOUSE MODEL THAT FOCUSES ON THE ONSET OF ALLERGIC ASTHMA EARLY IN LIFE AFTER AN IN-UTERO EXPOSURE TO ENVIRONMENTAL PARTICLES TO STUDY HOW MICROBIOME MAY LEAD TO THE ASTHMA ONSET. IN THIS MODEL, THE RESEARCH TEAM HAS SHOWN THAT MATERNAL EXPOSURES TO ALLERGEN OR PARTICULATE MATTER, E.G. CONCENTRATED URBAN AIR PARTICLES (CAP), DIESEL EXHAUST PARTICLES (DEP) AND TITANIUM DIOXIDE PARTICLES (TIO2), TRIGGER INCREASED ASTHMA RISK IN SEVERAL GENERATIONS OF THE OFFSPRING. HUMANS ARE WIDELY EXPOSED TO THESE PARTICULATES, ESPECIALLY IN URBAN AND INDUSTRIAL SETTINGS, WHERE THE INCIDENCE OF ASTHMA IS ALSO HIGHER. RESEARCHERS FOUND THAT THE INCREASED 'PREPAREDNESS' FOR ASTHMA IN THESE NEONATES IS ASSOCIATED WITH DNA METHYLATION CHANGES IN KEY IMMUNE CELLS DENDRITIC CELLS THAT ARE ESSENTIAL IN ASTHMA ORIGIN. IMPORTANT UNANSWERED QUESTIONS ARE WHY THESE EPIGENETIC CHANGES OCCUR, AND WHETHER THERE IS A CAUSATIVE LINK TO THE ABERRANT MICROBIOME SEEN IN ASTHMA. THE JCVI HYPOTHESIZE THAT IN UTERO EXPOSURES TO PARTICLES ALTER THE MICROBIOME OF THE PREGNANT MICE AND THEIR OFFSPRING, WHICH THEN SIGNALS TO THE IMMUNE CELLS IN A WAY THAT PREDISPOSES THE OFFSPRING TO ALLERGY. WE POSTULATE TWO, POTENTIALLY INTERCONNECTED, MECHANISMS IN ASTHMA ONSET: EPIGENETICS AND THE MICROBIOME. BOTH THE EPIGENETIC ALTERATIONS IN IMMUNE CELLS AND THE DYSBIOSIS IN THE GUT AND LUNG HAVE BEEN LINKED TO ASTHMA IN HUMANS AND MOUSE MODELS BUT CAUSALITY STUDIES ARE LACKING. THE PROPOSED RESEARCH ADDRESSES THIS GAP IN KNOWLEDGE IN A STUDY DESIGNED TO TEST BASIC MECHANISMS OF RELATIVELY COMMON ENVIRONMENTAL EXPOSURES. PROJECT FUNDED THROUGH THE NATIONAL INSTITUTE OF ALLERGY AND IMMUNOLOGY (NIAID/NIH) A DEVELOPMENT OF NOVEL PROTEIN-BASED VACCINE FORMULATIONS TO PREVENT PNEUMOCOCCAL COLONIZATION AND DISEASE WITH COLLABORATOR FROM THE UNIVERSITY OF MARYLAND. ONE OF THE MAJOR PROBLEMS OF THE GREAT BURDEN OF COMMUNITY-ACQUIRED PNEUMONIAS CAUSED BY STREPTOCOCCUS PNEUMONIAE (SPN) INFECTION, IS THE ACQUISITION OF ANTIMICROBIAL RESISTANCE AND THE GLOBAL SPREAD OF RESISTANT VARIANTS. THESE PROBLEMS GET ENHANCED BY THE MAJOR DISADVANTAGES OF THE CURRENT CAPSULAR POLYSACCHARIDE-BASED VACCINES, SUCH AS COST, SEROTYPE SPECIFICITY, AND THE RESULTING INCOMPLETE COVERAGE. THIS OCCURS MAINLY BECAUSE OF DISEASE BEING CAUSED BY SEROTYPES NOT PRESENT IN THE VACCINE (MAXIMUM OF 23 OF THE >97 CAPSULE TYPES, ONLY 13 IN THE CONJUGATE VACCINE) AND REPLACEMENT CARRIAGE. THE RATIONALE FOR THIS PROJECT IS THAT DEVELOPMENT OF A SUBUNIT-BASED VACCINE UTILIZING NOVEL CONSERVED ANTIGENIC PROTEINS IN CONJUNCTION WITH NOVEL POLYPHOSPHAZENE (PPZ) ADJUVANTS, PROVEN TO INDUCE ADAPTIVE IMMUNITY WILL DEEPEN THE CURRENT TOOLKIT TO PREVENT PNEUMOCOCCAL DISEASE WITHOUT SEROTYPE LIMITATIONS. THUS, JCVI HYPOTHESIZE THAT ADDITION OF CONSERVED IMMUNOGENIC PROTEINS TO A POTENT ADJUVANT NANO-MOLECULE WILL PROVIDE THE GROUNDWORK FOR THE DEVELOPMENT OF A BROADLY PROTECTIVE PNEUMOCOCCAL SUBUNIT-BASED VACCINE. (SEE FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED). | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $2,611,197 | ExpenseAmt |
| Grant | $59,968 | GrantAmt |
| Desc | JCVI IS THE RECIPIENT OF A LARGE COLLABORATIVE ASSISTANCE AWARD FROM THE US DEPARTMENT OF ENERGY. AWARDED TO THE VALUE OF $10.7M. NOW IN ITS 4TH YEAR OF 5,THE JCVI AND ITS COLLABORATORS, COLORADO STATE UNIVERSITY, VANDERBILT UNIVERSITY AND THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, SEEK TO LEVERAGE SIGNIFICANT RECENT ADVANCES IN DIATOM GENOME ENGINEERING AND METABOLIC MODELING; INCLUDING THE ABILITY TO INTRODUCE CHROMOSOME-LIKE EXPRESSION PLATFORMS, WHICH SUBSTANTIALLY ADVANCE POSSIBILITIES FOR HIGH-THROUGHPUT GENERATION AND SCREENING OF GENETICALLY ENGINEERED DIATOMS. RESEARCH PROPOSED HERE WILL RESULT IN DRAMATIC IMPROVEMENTS IN THE PREDICATIVE CAPACITY OF EXISTING GENOME SCALE METABOLIC MODELS OF DIATOM METABOLISM. FOR THE FIRST TIME ON A LARGE SCALE, FLUXOMICS, WHICH IS COMPOUND SPECIFIC INCORPORATION OF AN ISOTOPICALLY-LABELED FEEDSTOCK, WILL BE USED TO PROVIDE BETTER FIRST STEP CONSTRAINTS ON CO2 ASSIMILATION OF IN DIATOMS. STATE-OF-THE-ART HIGH THROUGHPUT IN VITRO EXAMINATIONS OF NEARLY ALL 200 DIATOM TRANSCRIPTION FACTORS WILL BE CONDUCTED TO BETTER UNDERSTAND REGULATORY ARCHITECTURE UNDERLYING DIATOM METABOLISM AS WELL AS SERVE AS A SOURCE FOR NEW TOOLS FOR GENOME ENGINEERING. TAKEN TOGETHER, RESEARCH PROPOSED HERE WILL ADDRESS CURRENTLY LIMITING BOTTLENECKS THROUGH FOSTERING STATE-OF-THE-ART INTEGRATION OF GENOME-SCALE MODELING WITH GENOME ENGINEERING TO OPTIMIZE ENERGY AND METABOLITE FLUX THROUGH SUBCELLULAR COMPARTMENTS TO PROMOTE EFFICIENT PRODUCTION OF HIGH VALUE AND FUEL-RELATED METABOLITES. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $2,679,430 | ExpenseAmt |
| Desc | DURING 2020, JCVI HAD MULTIPLE ACTIVE RESEARCH AWARDS FROM THE DEPARTMENT OF DEFENSE (DOD). THESE AWARDS FOCUS ON THE UNDERSTANDING OF POLYMICROBIAL INFECTIONS IN WOUNDS, THE DEVELOPMENT OF SYNTHETIC GENOMIC TECHNOLOGIES FOR MANIPULATION OF CHROMOSOMES AND GENOMES AND FOR THE DEVELOPMENT OF SAFE METHODS FOR DNA ISOLATION AND ANALYSIS FROM BIOTHREAT AGENTS. FUNDED BY THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA) THE JCVI IS PROVIDING LONGITUDINAL DNA METHYLATION PROFILING, LONGITUDINAL HISTONE MODIFICATION PROFILING AND LONGITUDINAL METABOLOME PROFILING ON MULTIPLE SAMPLES IN COLLABORATION WITH DARPA FOR THE SELECTING ELITE-PERFORMERS WITH LONGITUDINAL EPIGENOMIC CHARACTERIZATION AND TRACKING (SELECT) PROJECT. WOUND MICROBIOME PROJECT - CHRONIC WOUNDS ARE WOUNDS THAT FAIL TO HEAL AFTER 3 MONTHS UNDER STANDARD OF CARE WOUND MANAGEMENT. THE GOAL OF THIS DOD STUDY IS TO GAIN A BETTER UNDERSTANDING OF THE DIFFERENT CLASSES OF MICROBES THAT COULD BE PRESENT IN HUMAN CHRONIC WOUNDS (I.E. THE WOUND MICROBIOME), AND ASK WHETHER SPECIFIC MICROBES OR MICROBIAL COMMUNITIES ARE ASSOCIATED WITH NON-HEALING WOUNDS. NEXT GENERATION SEQUENCING WILL BE USED TO IDENTIFY AND CATALOG THE MICROBIAL SPECIES OF BACTERIA, FUNGI, AND VIRUSES THAT ARE PRESENT IN CHRONIC WOUND SPECIMENS. COMPUTATIONAL AND BIOINFORMATICS ANALYSES OF THE MICROBIAL COMMUNITY DNA SEQUENCES WILL BE CARRIED OUT TO CHARACTERIZE THE PRESENCE ANY PATHOGENIC, VIRULENCE, AND ANTIMICROBIAL RESISTANCE-RELATED GENES AND PATHWAYS. THE EVENTUAL GOAL IS TO IDENTIFY ANY PATHOGENIC SPECIES OR FEATURES THAT ARE ASSOCIATED WITH NON-HEALING WOUNDS, AND COULD BE USED AS DIAGNOSTIC AND TREATMENT TARGETS OF CHRONIC WOUNDS. SYNTHETIC ENGINEERING OF BACTERIOPHAGE FOR TREATMENT OF WOUND INFECTIONS ANTIMICROBIAL RESISTANCE IN BACTERIAL PATHOGENS IS STEADILY INCREASING AND RECOGNIZED AS ONE OF THE GREATEST THREATS TO GLOBAL PUBLIC HEALTH. SHORTLY AFTER THE BEGINNING OF THE WARS IN AFGHANISTAN AND IRAQ, THE MILITARY HEALTH SYSTEM EXPERIENCED A MAJOR INCREASE IN WOUND AND HEALTHCARE-ASSOCIATED INFECTIONS CAUSED BY MULTIDRUG RESISTANT ORGANISMS (MDROS) WITH EXTREMELY LIMITED TREATMENT OPTIONS. FUNDED THROUGH THE US MEDICAL RESEARCH ACQUISITION ACTIVITY, THE JCVI IN COLLABORATION WITH THE MILITARY AND THE WALTER REED ARMY INSTITUTE OF RESEARCH, IS COLLABORATING WITH THE GOAL TO DESIGN, BUILD, TEST AND CHARACTERIZE NOVEL ENGINEERED BACTERIOPHAGE BIOLOGICS SPECIFICALLY TARGETING MDROS FOR USE AS NOVEL THERAPEUTICS FOR TREATING AND PREVENTING COMBAT WOUND INFECTIONS USING PIONEERING TECHNOLOGY DEVELOPED AT JCVI. THIS OBJECTIVE WILL BE ACCOMPLISHED THROUGH EXPERIMENTS FOCUSED ON PRODUCING SYNTHETICALLY ENGINEERED PHAGE WITH AN ENHANCED HOST RANGE SUFFICIENT TO COVER CURRENT AND FUTURE CIRCULATING MDR STRAINS OF S. AUREUS AND K. PNEUMONIAE COMMONLY FOUND IN THE MILITARY HEALTH SYSTEM, INCLUDING METHICILLIN-RESISTANT S. AUREUS AND CARBAPENEM-RESISTANT K. PNEUMONIAE STRAINS. CANDIDATE ENGINEERED THERAPEUTIC PHAGE CHASSIS WILL BE PRODUCED, CHARACTERIZED AND TESTED IN MOUSE WOUND INFECTION MODELS BY RESEARCHERS AT WRAIR AS A PRELUDE TO FUTURE HUMAN USE. IT IS ANTICIPATED THAT WE WILL DEVELOP ONE OR MORE PHAGE CHASSIS CAPABLE OF SPECIFICALLY TARGETING AND KILLING EACH PATHOGEN BOTH IN VITRO AND IN VIVO." | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $3,873,475 | ExpenseAmt |
| Desc | OTHER PROGRAM SERVICES IN THE JCVI RESEARCH PORTFOLIO ALSO INCLUDED SUPPORT FROM FOUNDATIONS AND INDUSTRIAL COLLABORATIONS.: NATIONAL SCIENCE FOUNDATION COLLABORATIVE RESEARCH: IRON BIOAVAILABILITY IN HIGH-CO2 OCEANS: NEW PERSPECTIVES ON IRON ACQUISITION MECHANISMS IN DIATOMS WITH THIS PROJECT THE JCVI SEEKS TO UNDERSTAND THE DIFFERENTIAL SENSITIVITY OF DIATOM IRON ACQUISITION STRATEGIES TO CHANGES IN SEAWATER PH AND CARBONATE CHEMISTRY. ULTIMATELY A MORE THOROUGH AND DETAILED MECHANISTIC UNDERSTANDING OF DIATOM IRON UPTAKE PATHWAYS WILL FACILITATE A MUCH-IMPROVED ABILITY TO FORECAST THE IMPACT OF ANTICIPATED CHANGES IN OCEAN PH AND INORGANIC CARBON CHEMISTRY ON RATES OF IRON UPTAKE BY DIATOMS. THIS CRITICAL BIOGEOCHEMICAL ISSUE IS ADDRESSED THROUGH TRACE METAL CLEAN MANIPULATION EXPERIMENTS INCORPORATING STATE-OF-THE-ART ANALYTICAL METHODOLOGY TO PROBE PHYTOPLANKTON CELLULAR PHYSIOLOGY AND BIOGEOCHEMISTRY IN LABORATORY CULTURES AND NATURAL COMMUNITIES. IN THE FIRST YEAR, LABORATORY EXPERIMENTS WITH A MODEL PENNATE DIATOM LEVERAGE A COLLECTION OF TARGETED KNOCKOUT TRANSGENIC LINES TO EVALUATE THE SUBSTRATE SPECIFICITY AND RELATIVE IMPORTANCE OF DISTINCT IRON ASSIMILATION PATHWAYS UNDER A RANGE OF PCO2 AND IRON AVAILABILITY CONDITIONS. ADDITIONALLY, QUANTITATION OF MRNA AND PROTEINS FOR KEY DIATOM IRON ASSIMILATION PATHWAYS IN NATURAL COMMUNITIES IN THE SOUTHERN CALIFORNIA CURRENT FURTHER CLARIFY THE RELATIVE IMPORTANCE AND SENSITIVITY OF DISTINCT IRON ASSIMILATION PATHWAYS IN RELATION TO PCO2 AND IRON AVAILABILITY. IN YEAR TWO A LAGRANGIAN STUDY OF IRON UPTAKE RATES AND ASSOCIATED MRNA AND PROTEIN ABUNDANCE IS PERFORMED ON UPWELLED HIGH PCO2 WATER OVER THE COURSE OF OFFSHORE ADVECTION. ADDITIONALLY, WE CONDUCT MESOCOSM EXPERIMENTS USING NATURALLY ELEVATED HIGH PCO2 SEAWATER AS WELL AS LABORATORY EXPERIMENTS ON MULTIPLEX KNOCKOUT LINES. YEAR THREE IS DEDICATED TO DATA ANALYSES AND OVERALL PROJECT SYNTHESIS. OVERALL AIMS OF THE RESEARCH ACTIVITIES INCLUDE, 1) DEVELOPMENT AND VALIDATION OF A REFINED CONCEPTUAL MODEL OF IRON UPTAKE IN KEY MARINE PHYTOPLANKTON AND SUBSEQUENT UTILIZATION OF THE MODEL TO CHARACTERIZE THE SENSITIVITY OF DISTINCT IRON UPTAKE PATHWAYS TO THE EFFECTS OF OCEAN ACIDIFICATION, AND 2) DETERMINATION OF THE EFFECTS OF ACIDIFICATION ON IRON UPTAKE, AND QUANTIFICATION OF THE RELATIVE CONTRIBUTION OF DISTINCT IRON ACQUISITION PATHWAYS IN HIGH PCO2 PHYTOPLANKTON COMMUNITIES. GORDON AND BETTY MOORE FOUNDATION GENETIC DIVERSITY IS A HALLMARK OF ADAPTABILITY; THE RIGHT AMOUNT GIVES A THEORETICAL ADVANTAGE IN SHIFTING ENVIRONMENTS. HOWEVER, TOO MUCH DIVERSITY MAY LEAD TO DECREASED FITNESS RESULTING FROM GENETIC BOTTLENECKS, KNOWN AS MULLER'S RATCHET. THE EXTENT OF GENETIC VARIATION AMONG INDIVIDUALS CAN SET A SPECIES' ADAPTIVE POTENTIAL AND INFLUENCE ITS PERSISTENCE OVER TIME. FOR THESE REASONS, THE AMOUNT OF GENETIC VARIABILITY WITHIN SPECIES HAS BEEN A FOCUS OF POPULATION GENETICS AND EVOLUTIONARY BIOLOGY FOR NEARLY 100 YEARS. FROM AN ECOLOGICAL PERSPECTIVE, RECENT WORK IN BOTH TERRESTRIAL AND MARINE SYSTEMS HAS SHOWN THAT INTRASPECIFIC GENETIC DIVERSITY CAN MODULATE INTERSPECIFIC INTERACTIONS AND THUS INFLUENCE LEVELS OF PRIMARY PRODUCTIVITY AND FUNCTIONAL RESPONSES TO CHANGING ENVIRONMENTS. THESE COMPLEXITIES GUIDE OUR RATIONALE FOR SEEKING CELLULAR-LEVEL DATA TO ADDRESS HIGHER-ORDER ECO-EVOLUTIONARY DYNAMICS. IN THIS PROJECT, FUNDED BY THE GORDON AND BETTY MOORE FOUNDATION, THE JCVI HAVE TAKEN A CELLULAR APPROACH TO CAPTURE GENETIC DIVERSITY OF A MARINE EUKARYOTIC PHYTOPLANKTON POPULATION OF CYLINDROTHECA. DURING THIS WORK, JCVI HAS ISOLATED NOVEL RNA VIRUSES INFECTING THIS DIATOM AND GENERATED HOST/VIRUS GENOMIC AND TRANSCRIPT EXPRESSION DATA. JCVI HAVE ALSO DEVELOPED NEW AND MORE EFFICIENT METHODS FOR OBTAINING THESE DATA. USING THIS INFORMATION, WE HAVE EMPIRICALLY DERIVED THE HETEROGENEOUS NATURE OF PHYTOPLANKTON POPULATIONS AND GAINED INSIGHT INTO HOW THE INDIVIDUAL'S METABOLIC CAPACITY MAY NOT TRANSLATE TO THE POPULATION AS A WHOLE. THE LARRY L HILLBOM FOUNDATION - OVER THE LAST FEW YEARS, ADVANCES IN STEM CELL RESEARCH AND SYNTHETIC BIOLOGY HAVE CATALYZED AN EXTRAORDINARY EXPANSION OF ORGANOID TECHNOLOGY THAT IS BRINGING CHANGES TO TRANSLATIONAL MEDICINE, PHARMACEUTICAL RESEARCH, AND STRATEGIES FOR TREATING VARIOUS HUMAN PATHOLOGIES. USING STEM CELLS, ORGANOIDS HAVE BEEN DEVELOPED FOR MULTIPLE ORGANS INCLUDING LIVER, INTESTINE, KIDNEY, BRAIN, STOMACH, SKIN, OVARY, AND LUNG (1). A NETWORK OF SCIENTISTS LED BY THE JCVI AND IN COLLABORATION WITH STANFORD UNIVERSITY, UNIVERSITY OF CALIFORNIA, SAN DIEGO, AND THE SALK INSTITUTE FOR BIOLOGICAL STUDIES ARE DEVELOPING ORGANOIDS THAT CAN SERVE AS SURROGATES FOR BETA CELLS, WHICH ARE THE CELLS IN THE HUMAN PANCREAS THAT CONTROL BLOOD GLUCOSE LEVELS BY SYNTHESIZING INSULIN. THE GOAL IS THAT THESE ORGANOIDS, WHEN IMPLANTED IN TYPE 1 DIABETICS (T1D), WILL RESULT IN A BETTER TREATMENT AND BETTER LIVES FOR THOSE PATIENTS. THE INSULIN INFUSION PUMPS USED BY MANY T1D PATIENTS ARE IN ESSENCE, MECHANICAL ORGANOIDS. WHILE EFFECTIVE, THEY DO NOT COMPLETELY PROTECT THE PATIENTS FROM THE LONG-TERM EFFECTS OF THE DISEASE OR ENABLE A NORMAL NONDIABETIC LIFESTYLE. IN T1D PATIENTS, THE PANCREATIC BETA CELLS ARE DESTROYED BY AN AUTOIMMUNE RESPONSE. ONE THEME OF RESEARCH FOR MANY YEARS HAS BEEN TO TRANSPLANT BETA CELLS FROM CADAVERS INTO DIABETIC PATIENTS. MORE RECENTLY, RESEARCHERS ARE DEVELOPING METHODS TO PROGRAM STEM CELLS TO BECOME BETA CELLS THAT WOULD BE TRANSPLANTED INTO PATIENTS. FOR THIS TO BE SUCCESSFUL, THE PATIENTS ARE FORCED TO TAKE IMMUNOSUPPRESSIVE DRUGS FOR THE REST OF THEIR LIVES, OR TO SEQUESTER THE TRANSPLANTED BETA CELLS FROM THE PATIENT'S IMMUNE SYSTEM BY PLACING THEM IN PLASTIC CAPSULES. NEITHER OF THESE APPROACHES HAVE PROVEN SATISFACTORY. SUPPORT FROM LARRY L HILLBOM FOUNDATION IS ENABLING THE RESEARCH TEAM TO TEST TWO NOVEL APPROACHES TO MAKE INSULIN-PRODUCING BIOLOGICAL ORGANOIDS THAT WOULD CONTROL DIABETICS' BLOOD GLUCOSE LEVELS BUT NOT BE AFFECTED BY THE PATIENTS' AUTOIMMUNE SYSTEM, WHICH KILLED THE PATIENTS' NATURAL BETA CELLS. THE FIRST APPROACH IS TO USE STEM CELL AND SYNTHETIC BIOLOGY TECHNOLOGY TO DEVELOP ORGANOIDS THAT RESEMBLE THE EYE AND USE THEM TO HOUSE BETA CELLS. THE EYE IS A WELL-CHARACTERIZED "IMMUNE PRIVILEGE" SITE WHERE IMMUNE ACTIVITY IS REDUCED TO ALLOW FOR OTHER ESSENTIAL FUNCTIONS. THE GENERATED EYE/BETA CELL ORGANOIDS WILL BE IMPLANTED IN THE PATIENT'S SKIN AND REPLACE THE CURRENT INSULIN INFUSION THERAPY. THE SECOND APPROACH CAPITALIZES ON THE RECENT DISCOVERY BY THE RESEARCH TEAM THAT BACTERIA LIVE IN THE DEEPEST LAYERS OF THE SKIN. WE PROPOSE TO HARVEST THOSE BACTERIA AND USING SYNTHETIC BIOLOGY, GENETICALLY ENGINEER THEM TO SENSE BLOOD GLUCOSE IN THE SKIN AND SYNTHESIZE INSULIN IN RESPONSE TO ELEVATED GLUCOSE LEVELS. THEY WOULD BE ORGANOIDS THAT ARE LIKE NATURAL BETA CELLS, BUT NOT AFFECTED BY PATIENTS' AUTOIMMUNE RESPONSES. ORGANOIDS FROM BOTH APPROACHES SHOULD ENABLE AN AUTONOMOUS, CLOSED-LOOP SYSTEMS THAT ARE NOT MACHINEBASED WITH NO PAINFUL NEEDLES AND NO SENSATION OF WEARING A DEVICE. WE BELIEVE THAT ORGANOID-BASED THERAPIES COULD BE A BREAKTHROUGH THAT WILL BRING NORMAL LIFESTYLES TO T1D PATIENTS.SYNTHETIC-GESTALT - MORE AND MORE CHEMICALS TO SUPPORT VARIOUS INDUSTRIES WILL COME FROM ENGINEERED BACTERIA IN THE FUTURE, BUT CONCERNS REMAIN ABOUT THE SAFETY OF THE ORGANISMS OR UNINTENDED BYPRODUCTS. MINIMAL BACTERIAL CELLS OFFER A UNIQUE PLATFORM FOR BIOPRODUCTION. BECAUSE A LARGER FRACTION OF BIOLOGICAL PROCESSES ARE UNDERSTOOD IN THESE SIMPLE CELLS, THEY CAN EASILY BE MADE SAFE AND MORE EFFICIENT IN PRODUCING TARGET COMPOUNDS. THE COLLABORATION BETWEEN SYNTHETIC GESTALT AND JCVI IN 2020 LED TO THE DEVELOPMENT OF A DIGITAL TWIN, A COMPUTATIONAL MODEL, FOR A MINIMAL CELL THAT CAN BE USED TO OPTIMIZE METABOLIC REACTIONS IN THE CELL. THIS RESEARCH ALSO GAVE RISE TO STRAINS WITH METABOLIC PATHWAY GENES ADDED FROM OUTSIDE TOWARD ESTABLISHING A MINIMAL BACTERIAL CELL AS A FUTURE INDUSTRIAL PRODUCTION HOST. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $3,873,475 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $17,028,890 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | Yes (1) | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | 0 | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 56 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 180 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | Yes (1) | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 8 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 5 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | DR JOHN CRAIG VENTER | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 8582001800 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4120 CAPRICORN LANE | AddressLine1Txt |
| City | LA JOLLA | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 92037 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (20 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Key EmployeeKeyEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| VENTER JOHN CRAIG | ||||||||
| CHAIRMAN & CEO | 40.00 | Yes (X) | Yes (X) | $1,194,335 | $0 | $45,300 | ||
| NELSON KAREN | ||||||||
| PRESIDENT | 40.00 | Yes (X) | Yes (X) | $711,001 | $0 | $61,532 | ||
| KOWALSKI HEATHER | ||||||||
| CHIEF OPERATING OFFICER | 40.00 | Yes (X) | Yes (X) | $449,321 | $0 | $36,738 | ||
| MULLEN JILL | ||||||||
| SR. VP OF PHILANTHROPY AND STRATEGIC ALLIANCES | 40.00 | $350,060 | $0 | $63,009 | Yes (X) | |||
| SCHEUERMANN RICHARD H | ||||||||
| DIRECTOR, LA JOLLA CAMPUS | 40.00 | $348,827 | $0 | $56,459 | Yes (X) | |||
| STOUT MARTIN | ||||||||
| CHIEF TECHNOLOGY OFFICER | 40.00 | $308,171 | $0 | $36,227 | Yes (X) | |||
| PEAKE ANTONY G | ||||||||
| VP FOR RESEARCH ADMINISTRATION | 40.00 | $294,523 | $0 | $30,633 | Yes (X) | |||
| YUMULMARY | ||||||||
| VP OF HUMAN RESOURCES | 40.00 | $253,229 | $0 | $65,398 | Yes (X) | |||
| KIRKNESS EWEN | ||||||||
| PROFESSOR | 40.00 | $257,034 | $0 | $54,754 | Yes (X) | |||
| STAYEAS TIMOTHY | ||||||||
| NETWORK TEAM LEAD | 40.00 | $214,440 | $0 | $60,471 | Yes (X) | |||
| ADELSON JULIE | ||||||||
| VP, LEG. AFFRS/GENERAL COUNSEL | 40.00 | Yes (X) | $210,151 | $0 | $36,765 | |||
| PRATTE EDWARD | ||||||||
| DIRECTOR OF SECURITY | 40.00 | $226,695 | $0 | $7,187 | Yes (X) | |||
| FRIEDMAN ROBERT M | ||||||||
| VP FOR POLICY & UNIV. RELATIONS | 40.00 | $143,182 | $0 | $52,666 | Yes (X) | |||
| BADR-EL-DIN AMIN PHD | ||||||||
| TRUSTEE | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| HOROWITZREENA | ||||||||
| TRUSTEE (THRU 2/27/2020) | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| KNIGHT JESSIE | ||||||||
| TRUSTEE (THRU 2/27/2020) | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| MCGRORY JACK | ||||||||
| TRUSTEE | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| NORRBY ERLING | ||||||||
| TRUSTEE | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| RUGGLES RUDY | ||||||||
| TRUSTEE | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| WEI WU | ||||||||
| TRUSTEE (AS OF 2/27/2020) | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,960,969 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $607,139 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 58 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (2 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| TB CONSULTING | |||||
| 8328 E HARTFORD DRIVE SUITE 102 | SCOTTSDALE | AZ | 85255 | COMPUTER SERVICE CONSULTANT | $216,901 |
| MOSS ADAMS LLP | |||||
| 4747 EXECUTIVE DRIVE SUITE 1300 | SAN DIEGO | CA | 92121 | ACCOUNTING AND AUDIT SERVICES | $165,285 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 2 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $15,140,853 | GovernmentGrantsAmt |
| All Other Contributions | $3,472,566 | AllOtherContributionsAmt |
| Total Contributions | $18,613,419 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| SEQUENCING SERVICES REVENUE | 900099 | $120,988 | $120,988 |
| CLONE REVENUE | 900099 | $2,667 | $2,667 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $123,655 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $905,885 | TotalRevenueColumnAmt |
| Exclusion | $905,885 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $8,729,641 | SecuritiesAmt |
| Other | $95,018 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $10,552,212 | SecuritiesAmt |
| Other | $2,091 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | -$1,822,571 | SecuritiesAmt |
| Other | $92,927 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$1,729,644 | TotalRevenueColumnAmt |
| Exclusion | -$1,729,644 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | K-1 PASSTHROUGH | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $15,294 | TotalRevenueColumnAmt |
| Unrelated Business Revenue | $15,294 | UnrelatedBusinessRevenueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $15,294 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $17,928,609 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $123,655 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $15,294 | UnrelatedBusinessRevenueAmt |
| Exclusion | -$823,759 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,782,839 | TotalAmt |
| Program Services | $2,782,839 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $59,968 | TotalAmt |
| Program Services | $59,968 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,015,830 | TotalAmt |
| Program Services | $1,037,747 | ProgramServicesAmt |
| Management And General | $2,945,546 | ManagementAndGeneralAmt |
| Fundraising | $32,537 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,209,265 | TotalAmt |
| Program Services | $7,678,994 | ProgramServicesAmt |
| Management And General | $4,135,691 | ManagementAndGeneralAmt |
| Fundraising | $394,580 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $407,174 | TotalAmt |
| Program Services | $202,230 | ProgramServicesAmt |
| Management And General | $182,191 | ManagementAndGeneralAmt |
| Fundraising | $22,753 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,476,838 | TotalAmt |
| Program Services | $674,939 | ProgramServicesAmt |
| Management And General | $706,100 | ManagementAndGeneralAmt |
| Fundraising | $95,799 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,015,671 | TotalAmt |
| Program Services | $430,211 | ProgramServicesAmt |
| Management And General | $537,894 | ManagementAndGeneralAmt |
| Fundraising | $47,566 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $54,871 | TotalAmt |
| Management And General | $54,871 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $133,112 | TotalAmt |
| Management And General | $133,112 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $108,379 | TotalAmt |
| Management And General | $108,379 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $210,121 | TotalAmt |
| Program Services | $70,000 | ProgramServicesAmt |
| Management And General | $140,121 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $37,579 | TotalAmt |
| Management And General | $37,579 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $361,311 | TotalAmt |
| Program Services | $121,628 | ProgramServicesAmt |
| Management And General | $221,868 | ManagementAndGeneralAmt |
| Fundraising | $17,815 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $973,958 | TotalAmt |
| Program Services | $31,911 | ProgramServicesAmt |
| Management And General | $942,047 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,041,396 | TotalAmt |
| Program Services | $1,371,259 | ProgramServicesAmt |
| Management And General | $626,438 | ManagementAndGeneralAmt |
| Fundraising | $43,699 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,595 | TotalAmt |
| Program Services | $17,920 | ProgramServicesAmt |
| Management And General | $4,647 | ManagementAndGeneralAmt |
| Fundraising | $8,028 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $52,041 | TotalAmt |
| Program Services | $44,395 | ProgramServicesAmt |
| Management And General | $6,505 | ManagementAndGeneralAmt |
| Fundraising | $1,141 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $66,954 | TotalAmt |
| Management And General | $66,954 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,051,976 | TotalAmt |
| Program Services | $1,051,885 | ProgramServicesAmt |
| Management And General | $984,247 | ManagementAndGeneralAmt |
| Fundraising | $15,844 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $477,540 | TotalAmt |
| Program Services | $108,701 | ProgramServicesAmt |
| Management And General | $366,868 | ManagementAndGeneralAmt |
| Fundraising | $1,971 | FundraisingAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| LAB EQUIPMENT/SUPPLIES | $1,726,041 | $1,335,945 | $390,096 | |
| BOOKS AND SUBSCRIPTIONS | $26,646 | $36 | $21,646 | $4,964 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $54,674 | TotalAmt |
| Program Services | $8,282 | ProgramServicesAmt |
| Management And General | $46,277 | ManagementAndGeneralAmt |
| Fundraising | $115 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,374,779 | TotalAmt |
| Program Services | $17,028,890 | ProgramServicesAmt |
| Management And General | $12,659,077 | ManagementAndGeneralAmt |
| Fundraising | $686,812 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,765,643 | BOYAmt |
| EOY | $2,188,334 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,285,562 | BOYAmt |
| EOY | $7,177,016 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,868,838 | BOYAmt |
| EOY | $4,135,631 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $260,317 | BOYAmt |
| EOY | $16,925 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,022,612 | BOYAmt |
| EOY | $884,675 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $69,065,155 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $24,415,322 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $46,530,181 | BOYAmt |
| EOY | $44,649,833 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $36,161,170 | BOYAmt |
| EOY | $37,353,456 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,253,071 | BOYAmt |
| EOY | $1,087,432 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,840,214 | BOYAmt |
| EOY | $2,776,513 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $108,987,608 | BOYAmt |
| EOY | $100,269,815 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,031,343 | BOYAmt |
| EOY | $4,481,086 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,528,751 | BOYAmt |
| EOY | $2,353,045 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $26,524,485 | BOYAmt |
| EOY | $24,942,805 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $82,679 | BOYAmt |
| EOY | $5,077,885 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $35,167,258 | BOYAmt |
| EOY | $36,854,821 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $73,084,655 | BOYAmt |
| EOY | $62,937,864 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $735,695 | BOYAmt |
| EOY | $477,130 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $73,820,350 | BOYAmt |
| EOY | $63,414,994 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $108,987,608 | BOYAmt |
| EOY | $100,269,815 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$12,446,170 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $2,056,108 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$15,294 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $26,768,604 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $20,421,917 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $30,012,027 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $21,442,951 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $18,613,419 | CurrentTaxYearAmt |
| Total | $117,258,918 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $26,768,604 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $20,421,917 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $30,012,027 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $21,442,951 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $18,613,419 | CurrentTaxYearAmt |
| Total | $117,258,918 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $4,002,103 | SubstantialContributorsTotAmt |
| Public Support Total170 | $113,256,815 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,482,196 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,373,809 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,387,304 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,158,537 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $905,885 | CurrentTaxYearAmt |
| Total | $6,307,731 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $123,566,649 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $1,757,477 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.91660 | PublicSupportCY170Pct |
| Public Support PY170 | 0.76300 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Assets Included | $2,545,000 | AssetsIncludedAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Pub Exhibition | Yes (X) | CollectionUsedPubExhibitionInd |
| Coll Used Scholarly Rsrch | Yes (X) | CollUsedScholarlyRsrchInd |
| Collection Used Preservation | Yes (X) | CollectionUsedPreservationInd |
| Solicited Assets Sale | 0 | SolicitedAssetsSaleInd |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $53,875,009 | OtherCostOrOtherBasisAmt |
| Depreciation | $10,050,198 | DepreciationAmt |
| Book Value | $43,824,811 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $15,190,146 | OtherCostOrOtherBasisAmt |
| Depreciation | $14,365,124 | DepreciationAmt |
| Book Value | $825,022 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $44,649,833 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| LEASES PAYABLE | $33,024 |
| PPP LOAN | $5,044,861 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $5,077,885 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $20,221,044 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $2,056,108 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $360,000 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | $2,416,108 | RevenueNotReportedAmt |
| Revenue Subtotal | $17,804,936 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $108,379 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $15,294 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $123,673 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $17,928,609 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $30,626,400 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $360,000 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $360,000 | ExpensesNotReportedAmt |
| Expenses Subtotal | $30,266,400 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $108,379 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $108,379 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $30,374,779 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART III, LINE 4: | COLLECTION OF SCIENTIFIC WRITINGS RELEVANT TO GENOMIC RESEARCH. |
| PART X, LINE 2: | THE INSTITUTE IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE INSTITUTE DOES NOT BELIEVE THERE ARE ANY MATERIAL UNCERTAIN TAX POSITIONS AND ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE INSTITUTE IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIOD IN PROGRESS. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | K-1 PASSTHROUGH 15,294. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)
| RegionRegionTxt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|
| EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, | PROGRAM SERVICES | RESEARCH SUBGRANTS | $59,986 |
| CAYMAN ISLANDS | INVESTMENTS | $143,279 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $203,265 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $203,265 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | EAST ASIA AND THE PACIFIC | RegionTxt |
| Purpose Of Grant | PROGRAM SERVICES | PurposeOfGrantTxt |
| Cash Grant | $59,986 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | Yes (1) | PassiveForeignInvestmestCoInd |
| Foreign Partnership | Yes (1) | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. |
| PART I, LINE 3: | ACCRUAL BASIS |
| PART III ACCOUNTING METHOD: | |
| PART II, LINE 1: | ACCRUAL BASIS |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (14 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF CALIFORNIA SAN DIEGO | |||||||
| 9500 GILMAN DR | LA JOLLA | CA | 92037 | 566001393 | 501(C)(3) | $646,423 | RESEARCH SUBGRANT |
| UNIVERSITY OF CALIFORNIA IRVINE | |||||||
| 120 THEORY SUITE 200 | IRVINE | CA | 92697 | 952226406 | 501(C)(3) | $73,149 | RESEARCH SUBGRANT |
| COLORADO STATE UNIVERSITY | |||||||
| 6015 CAMPUS DELIVERY | FORT COLLINS | CO | 80523 | 846000545 | 501(C)(3) | $441,120 | RESEARCH SUBGRANT |
| MRI GLOBAL | |||||||
| 425 VOLKER BLVD | KANSAS CITY | MO | 641102241 | 440545878 | 501(C)(3) | $117,251 | RESEARCH SUBGRANT |
| REGENTS UNIVERSITY OF MINNESOTA | |||||||
| 700 ROSEDALE AVE | ST LOUIS | MO | 63112 | 430653611 | 501(C)(3) | $46,643 | RESEARCH SUBGRANT |
| VANDERBILT UNIVERSITY | |||||||
| 2201 WEST END AVE | NASHVILLE | TN | 37235 | 620476822 | 501(C)(3) | $236,730 | RESEARCH SUBGRANT |
| RHODE ISLAND HOSPITAL | |||||||
| 1 HOPPIN STREET BOX 42 SUITE 1300 | PROVIDENCE | RI | 029034923 | 050258954 | 501(C)(3) | $393,803 | RESEARCH SUBGRANT |
| SALK INSTITUTE | |||||||
| 10010 N TORREY PINES ROAD | LA JOLLA | CA | 92037 | 952160097 | 501(C)(3) | $123,771 | RESEARCH SUBGRANT |
| SANTA FE INSTITUTE | |||||||
| 1399 HYDE PARK ROAD | SANTA FE | NM | 875018943 | 850325494 | 501(C)(3) | $46,969 | RESEARCH SUBGRANT |
| SEQUELLA FOUNDATION INC | |||||||
| 9610 MEDICAL CENTER DRIVE 200 | ROCKVILLE | MD | 20850 | 522044703 | 501(C)(3) | $5,378 | RESEARCH SUBGRANT |
| LELAND STANFORD JR UNIVERSITY | |||||||
| 3145 PORTER DRIVE | PALO ALTO | CA | 94304 | 941156365 | 501(C)(3) | $254,611 | RESEARCH SUBGRANT |
| CAL POLY CORPORATION | |||||||
| 1 GRAND AVE | SAN LUIS OBSISPO | CA | 93407 | 951648180 | 501(C)(3) | $30,426 | RESEARCH SUBGRANT |
| GLOBAL ALGAE INNOVATIONS | |||||||
| 486 LIVE OAK DRIVE | EL CAJON | CA | 92020 | 455319556 | $326,567 | RESEARCH SUBGRANT | |
| LAWRENCE LIVERMORE NATIONAL LABORATORY | |||||||
| 7000 EAST AVE | LIVERMORE | CA | 94550 | 205624386 | GOVT | $40,000 | RESEARCH SUBGRANT |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 13 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Personal Services | Yes (X) | PersonalServicesInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VENTER JOHN CRAIG | ||||||||||||||
| CHAIRMAN & CEO | $1,178,618 | $0 | $0 | $0 | $15,717 | $0 | $11,400 | $0 | $33,900 | $0 | $1,239,635 | $0 | $0 | $0 |
| NELSON KAREN | ||||||||||||||
| PRESIDENT | $705,214 | $0 | $0 | $0 | $5,787 | $0 | $11,400 | $0 | $50,132 | $0 | $772,533 | $0 | $0 | $0 |
| KOWALSKI HEATHER | ||||||||||||||
| CHIEF OPERATING OFFICER | $446,179 | $0 | $0 | $0 | $3,142 | $0 | $11,400 | $0 | $25,338 | $0 | $486,059 | $0 | $0 | $0 |
| MULLEN JILL | ||||||||||||||
| SR. VP OF PHILANTHROPY AND STRATEGIC | $342,958 | $0 | $0 | $0 | $7,102 | $0 | $11,400 | $0 | $51,609 | $0 | $413,069 | $0 | $0 | $0 |
| SCHEUERMANN RICHARD H | ||||||||||||||
| DIRECTOR, LA JOLLA CAMPUS | $340,418 | $0 | $0 | $0 | $8,409 | $0 | $11,400 | $0 | $45,059 | $0 | $405,286 | $0 | $0 | $0 |
| STOUT MARTIN | ||||||||||||||
| CHIEF TECHNOLOGY OFFICER | $299,769 | $0 | $0 | $0 | $8,402 | $0 | $11,400 | $0 | $24,827 | $0 | $344,398 | $0 | $0 | $0 |
| PEAKE ANTONY G | ||||||||||||||
| VP FOR RESEARCH ADMINISTRATION | $291,936 | $0 | $0 | $0 | $2,587 | $0 | $11,400 | $0 | $19,233 | $0 | $325,156 | $0 | $0 | $0 |
| YUMULMARY | ||||||||||||||
| VP OF HUMAN RESOURCES | $250,697 | $0 | $0 | $0 | $2,532 | $0 | $10,400 | $0 | $54,998 | $0 | $318,627 | $0 | $0 | $0 |
| KIRKNESS EWEN | ||||||||||||||
| PROFESSOR | $256,212 | $0 | $0 | $0 | $822 | $0 | $10,400 | $0 | $44,354 | $0 | $311,788 | $0 | $0 | $0 |
| STAYEAS TIMOTHY | ||||||||||||||
| NETWORK TEAM LEAD | $212,920 | $0 | $0 | $0 | $1,520 | $0 | $8,986 | $0 | $51,485 | $0 | $274,911 | $0 | $0 | $0 |
| ADELSON JULIE | ||||||||||||||
| VP, LEG. AFFRS/GENERAL COUNSEL | $197,625 | $0 | $0 | $0 | $12,526 | $0 | $8,015 | $0 | $28,750 | $0 | $246,916 | $0 | $0 | $0 |
| PRATTE EDWARD | ||||||||||||||
| DIRECTOR OF SECURITY | $223,817 | $0 | $0 | $0 | $2,878 | $0 | $0 | $0 | $7,187 | $0 | $233,882 | $0 | $0 | $0 |
| FRIEDMAN ROBERT M | ||||||||||||||
| VP FOR POLICY & UNIV. RELATIONS | $126,606 | $0 | $0 | $0 | $16,576 | $0 | $5,305 | $0 | $47,361 | $0 | $195,848 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 1A | FormAndLineReferenceDesc |
| Explanation | SCHEDULE J, PART I, LINE 1A: TAX INDEMIFICATION AND GROSS-UP PAYMENTS - CERTAIN AWARDS ARE GROSSED UP FOR INCOME TAX AND INCLUDED AS TAXABLE COMPENSATION. SCHEDULE J, PART I, LINE 1A; FIRST-CLASS OR CHARTER TRAVEL - THE ORGANIZATION PROVIDES THE CEO FIRST CLASS AND CHARTER TRAVEL FOR BUSINESS PURPOSES. NO PART OF THIS BENEFIT IS TREATED AS TAXABLE COMPENSATION. SCHEDULE J, PART I, LINE 1A; PERSONAL SERVICES - THE ORGANIZATION PROVIDES THE CEO SERVICES OF BODYGUARDS WHEN HE TRAVELS. NO PART OF THIS BENEFIT IS TREATED AS TAXABLE COMPENSATION. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED): | THE GAPS IN KNOWLEDGE WE AIM TO BRIDGE ARE TO DEFINE AND CHARACTERIZE NOVEL PNEUMOCOCCAL ANTIGENIC PROTEINS AND POLYELECTROLYTE ADJUVANTS FORMULATIONS THAT WILL INITIATE ADAPTIVE IMMUNE RESPONSES AND LEAD TO PROTECTION AGAINST DISEASE IN A SEROTYPE INDEPENDENT MANNER. THE PROPOSED WORK IS SIGNIFICANT DUE TO THE HIGH INCIDENCE SEROTYPE REPLACEMENT THAT CURRENT POLYSACCHARIDE-BASED VACCINES ARE PRONE TO, WHICH LEADS TO INCREASE SUSCEPTIBILITY OF CHILDREN AND THE ELDERLY TO SPN CARRIAGE AND SEVERE INFECTIONS (E.G., PNEUMONIA, BACTEREMIA, AND MENINGITIS); AND INNOVATIVE SINCE IT WILL USE NOVEL FORMULATIONS OF ANTIGENIC AND CONSERVED PNEUMOCOCCAL PROTEINS TO INDUCE POTENT ADAPTIVE IMMUNE RESPONSES, THAT WILL NOT BE SEROTYPE DEPENDENT. FUNDED THROUGH THE NATIONAL INSTITUTE OF ALLERGY AND IMMUNOLOGY (NIAID/NIH) INTERPLAY BETWEEN THE HEAT SHOCK RESPONSE AND HISTIDINE KINASE PATHWAYS IN THE THERMALLY DIMORPHIC FUNGAL PATHOGEN HISTOPLASMA CAPSULATUM. HISTOPLASMA CAPSULATUM IS ONE OF SEVERAL SYSTEMIC DIMORPHIC FUNGAL PATHOGENS THAT SWITCH THEIR GROWTH PROGRAM FROM AN INFECTIOUS MOLD FORM IN THE SOIL TO A PATHOGENIC YEAST FORM IN MAMMALIAN HOSTS. H. CAPSULATUM CAUSES UP TO 25,000 LIFE-THREATENING INFECTIONS PER YEAR IN THE U.S. ALONE WITH UP TO 50% MORTALITY RATE AND IS THE MOST COMMON CAUSE OF FUNGAL RESPIRATORY INFECTIONS IN HEALTHY HOSTS. INFECTION OCCURS WHEN THE SOIL IS DISRUPTED, FACILITATING DISPERSION OF HYPHAL FRAGMENTS OR SPORES THAT ARE INHALED BY HUMANS. SPORES AND HYPHAL FRAGMENTS ARE THE PRIMARY INFECTIOUS AGENTS; HOWEVER, ONCE INTRODUCED INTO THE HOST, THE PATHOGEN CONVERTS TO A BUDDING-YEAST FORM, WHICH SURVIVES AND REPLICATES WITHIN HOST MACROPHAGES. HUMAN BODY TEMPERATURE IS THE PRIMARY SIGNAL FOR CONVERSION FROM AN INFECTIOUS TO A PARASITIC FORM IN HISTOPLASMA. DESPITE ITS IMPORTANCE TO HUMAN HEALTH, VERY LITTLE IS KNOWN ABOUT HOW H. CAPSULATUM SENSES AND RESPONDS TO HUMAN BODY TEMPERATURE. THE JCVI IN OUR FUNDED NIH R01 PROJECT, HAS PROPOSED TO BUILD UPON ITS PREVIOUS FINDINGS AND FULLY CHARACTERIZE THE INVOLVEMENT OF THE HEAT SHOCK RESPONSE AND HISTIDINE KINASE PATHWAYS IN REGULATING CELL MORPHOLOGY AND VIRULENCE TRAITS IN H. CAPSULATUM IN RESPONSE TO HOST TEMPERATURE. JCVI HAS BEEN WORKING ON IMPROVING H. CAPSULATUM GENOME ASSEMBLY. TO THIS END, IT USED LONG-READ SEQUENCING TECHNOLOGY AND SUCCESSFULLY COMPLETED CHROMOSOMAL LEVEL ASSEMBLIES OF FIVE COMMONLY USED HISTOPLASMA STRAINS, WHICH HAVE SIX OR SEVEN CHROMOSOMES. JCVI DESCRIBED ITS FINDINGS IN A MANUSCRIPT THAT IS CURRENTLY UNDER REVISION AT THE MBIO JOURNAL. JCVI WILL BE UTILIZING ITS NEW ASSEMBLIES AND ANNOTATIONS IN THE TRANSCRIPTOME STUDIES THAT IT HAS BEEN PERFORMING WITHIN THE SCOPE OF OUR FUNDED PROJECT. RESULTS OF THIS PROJECT WILL PROVIDE FUNDAMENTAL INFORMATION ON HOW CELLS SENSE TEMPERATURE AND TURN ON THE APPROPRIATE VIRULENCE PATHWAYS IN THE HOST. ULTIMATELY, THE INFORMATION OBTAINED FROM THIS PROJECT CAN BE USED TO DEVELOP THERAPEUTICS FOR H. CAPSULATUM INFECTIONS AND HELP PREVENT OTHER DIMORPHIC FUNGAL INFECTIONS. GREATER THAN 10% OF HIV PATIENTS INJECT ILLICIT DRUGS AND WITH THE RISING OPIOID CRISIS AND THE INCREASED RISK OF HIV IN THESE PATIENTS, IT IS CRITICAL WE UNDERSTAND HOW SUBSTANCE USE INFLUENCES THE SPREAD AND COURSE OF HIV INFECTION AND DISEASE. FUNDED BY THE NATIONAL INSTITUTE OF DRUG ABUSE (NIDA/NIH) AND IN COLLABORATION WITH BOSTON UNIVERSITY, THIS STUDY SPECIFICALLY ADDRESSES HOW OPIOID ABUSE ALTERS THE IMMUNE RESPONSE IN HIV PATIENTS AND WITH THIS CAN DIRECTLY CONTRIBUTE TO HIDDEN RESERVOIRS OF HIV. SUCCESSFUL COMPLETION OF THESE STUDIES WILL PROVIDE INSIGHTS INTO POTENTIAL STRATEGIES FOR TREATING HIV IN THIS GROWING POPULATION OF HIV PATIENTS. OUR CENTRAL HYPOTHESIS IS THAT OPIOID MISUSE EXACERBATES HIV PATHOGENESIS AND THE ESTABLISHMENT OF HIV LATENCY BY DYSREGULATING THE HOST IMMUNE RESPONSE. OUR OVERALL OBJECTIVE IS TO EXPLOIT TRANSCRIPTOMIC INFORMATION FROM PATIENT SAMPLES TO CHARACTERIZE THE EFFECTS OF OPIOID USE DISORDER ON HOST IMMUNE FUNCTION, HIV REPLICATION, AND HIV LATENCY. WE WILL CHARACTERIZE SINGLE CELL GENE EXPRESSION AND IDENTIFY DYSREGULATED GENE REGULATORY NETWORKS IN IMMUNE CELLS ASSOCIATED WITH OPIOID MISUSE IN PLWH. WE WILL ALSO PERFORM COMPUTATIONAL ANALYSIS TO IDENTIFY IMMUNE CELL GENE REGULATORY NETWORKS ALTERED BY OPIOID MISUSE AND WE WILL COMBINE SINGLE CELL RNA-SEQ AND FLUORESCENT IN SITU HYBRIDIZATION FLOW CYTOMETRY (FLOW-FISH) TO CHARACTERIZE THE TRANSCRIPTOME IN CELL MODELS OF LATENT HIV INFECTION. SUCCESSFUL COMPLETION OF THESE AIMS WILL HAVE SIGNIFICANT RESEARCH AND CLINICAL IMPACT BY: 1) ELUCIDATING HOW OPIOID MISUSE ALTERS HIV PATHOGENESIS; 2) PRODUCING NOVEL TOOLS FOR CHARACTERIZING HIV LATENCY; AND 3) DISCOVERING CANDIDATE MOLECULES TO REGULATE HIV EXPRESSION IN THE CONTEXT OF OPIOID MISUSE. SEVERAL ADDITIONAL DHHS GRANTS AT JCVI ARE RELATED TO HUMAN MICROBIOME STUDIES. THE MICROBIOME IS THE COLLECTION OF MICROBES THAT LIVE IN AND ON THE HUMAN BODY; THESE SPECIES HAVE RECEIVED CONSIDERABLE ATTENTION IN RECENT YEARS BECAUSE A NEW APPRECIATION OF THE COMPLEX ROLES THAT THEY PLAY IN HEALTH AND DISEASE. SOME OF THESE STUDIES ARE AIMED AT BASIC CHARACTERIZATION OF THE COMPOSITION AND ACTIVITY OF THE MICROBIOME, WHILE OTHERS SEEK TO UNDERSTAND THE CONTRIBUTION OF THE MICROBIOME TO THE DEVELOPMENT OF VARIOUS DISEASES INCLUDING ALCOHOLIC HEPATITIS, TYPE 1 DIABETES, DENTAL CARIES, DIARRHEA, AND ESOPHAGEAL CANCER, AMONG OTHERS. THE INSTITUTE IS AN ACTIVE PARTICIPATANT IN THE H3AFRICA PROGRAM VIA A COLLABORATION WITH THE UNIVERSITY OF CAPE TOWN, SOUTH AFRICA, TRAINING COLLABORATORS IN HUMAN MICROBIOME ANALYSIS. THE PROGRAM IS SPONSORED BY THE NIH COMMON FUND TO BRING TECHNOLOGICAL RESOURCES AND TRAINING IN A CAPITAL INVESTMENT-INTENSIVE FIELD (GENOMICS) TO THE AFRICAN CONTINENT VIA COLLABORATIONS WITH US SCIENTISTS WITH EXPERTISE IN THIS FIELD. |
| FORM 990, PART VI, SECTION A, LINE 2 | BOARD MEMBERS HEATHER KOWALSKI AND J. CRAIG VENTER HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS REVIEWED BY MANAGEMENT. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. |
| FORM 990, PART VI, SECTION B, LINE 12C | JCVI MONITORS COMPLIANCE OF ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL SOLICITATION OF CONFLICT OF INTEREST STATEMENTS FROM TRUSTEES, OFFICERS, AND EMPLOYEES. IF A PERSON HAS A CONFLICT WITH RESPECT TO A TRANSACTION, SUCH PERSON IS NOT ALLOWED TO VOTE. |
| FORM 990, PART VI, SECTION B, LINE 15 | JCVI USES AN OUTSIDE COMPENSATION CONSULTANT, TO PROVIDE A LIST OF COMPARABLE SALARIES FOR THE CEO AND OFFICERS THESE ARE REVIEWED BY THE JCVI COMPENSATION COMMITTEE AND CEO BEFORE A FINAL DETERMINATION IS MADE. THIS PROCESS WAS DOCUMENTED AND LAST DONE IN OCTOBER 2018. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| FORM 990, PART XI, LINE 9: | K-1 PASSTHROUGH -15,294. |
Schedule R IRS990ScheduleR
Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp
Related Organization Name RelatedOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | J CRAIG VENTER INSTITUTE MEDICAL GROUP | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4120 CAPRICORN LANE | AddressLine1Txt |
| City | LA JOLLA | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 92037 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 833574850 | EIN |
| Primary Activities | MEDICAL OFFICE | PrimaryActivitiesTxt |
| Legal Domicile State | CA | LegalDomicileStateCd |
| Direct Controlling NA | N/A | DirectControllingNACd |
| Entity Type | C | EntityTypeTxt |
| Ownership | 1.00000 | OwnershipPct |
| Controlled Organization | Yes (1) | ControlledOrganizationInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | 0 | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | Yes (1) | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Comments